Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer DOI Creative Commons
Marina Elena Cazzaniga, Foluso O. Ademuyiwa, Thierry Petit

et al.

JNCI Cancer Spectrum, Journal Year: 2023, Volume and Issue: 8(1)

Published: Dec. 19, 2023

Abstract In previously reported retrospective studies, high tumor RNA disruption during neoadjuvant chemotherapy predicted for post-treatment pathologic complete response (pCR) and improved disease-free survival at definitive surgery primary early breast cancer. The BREVITY (Breast Cancer Response Evaluation Individualized Therapy) prospective clinical trial (NCT03524430) seeks to validate these prior findings. Here we report training set (Phase I) findings, including determination of index (RDI) cut points outcome prediction in the subsequent validation II; 454 patients). 80 patients set, maximum RDI values biopsies obtained were significantly higher pCR responders than without (P = .008). Moreover, ≤3.7 treatment a lack (negative predictive value 93.3%). These findings support prospect that on-treatment assessments may effectively predict post-surgery outcome, possibly permitting optimization.

Language: Английский

The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients DOI
Zihang Zeng, Zongbi Yi, Binghe Xu

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: 616, P. 217574 - 217574

Published: Feb. 19, 2025

Language: Английский

Citations

1
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer DOI Creative Commons
Isaac García-Murillas, Rosalind J. Cutts,

Giselle Walsh-Crestani

et al.

Breast Cancer Research and Treatment, Journal Year: 2024, Volume and Issue: 209(3), P. 493 - 502

Published: Oct. 18, 2024

Detection of molecular residual disease (MRD) allows for the identification breast cancer patients at high-risk recurrence, with potential that early initiation treatment stages relapse could improve patient outcomes. The Invitae Personalized Cancer Monitoring™ assay (PCM) is a newly developed next-generation sequencing approach utilizes up to 50 patient-specific, tumor-informed DNA variants, detect circulating tumor (ctDNA). ability PCM MRD before clinical was evaluated. cohort included 61 female who underwent neoadjuvant chemotherapy. Plasma samples were collected and during therapy, after surgery monitoring. used ctDNA each time point. sensitivity in plasma from relapsed monitoring phase 76.9% (10/13). Specificity positive predictive values both 100% all (10/61, 16%) had detected subsequently relapsing. associated future (HR 37.2, 95% CI 10.5-131.9, p < 0.0001), median lead-time detection 11.7 months. long over relapse, shows strong association relapse-free survival may be identify allowing earlier intervention.

Language: Английский

Citations

6
Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives DOI Creative Commons
Sara Franzi,

Gabriele Seresini,

Paola Borella

et al.

Frontiers in Genetics, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 5, 2023

Introduction: To date, tissue biopsy represents the gold standard for characterizing non-small-cell lung cancer (NSCLC), however, complex architecture of disease has introduced need new investigative approaches, such as liquid biopsy. Indeed, DNA analyzed in is much more representative tumour heterogeneity. Materials and methods: We performed a meta-analysis 17 selected papers, to attest diagnostic performance identifying EGFR mutations NSCLC. Results: In overall studies, we found sensitivity 0.59, specificity 0.96 odds ratio 24,69. Since noticed high heterogeneity among different also separate subsets divided by 1) stage disease, 2) experimental design 3) method mutation detection. Liquid highest sensitivity/specificity high-stage tumours, prospective studies are reliable than retrospective ones terms specificity, both NGS PCR-based techniques can be used detect Discussion: Overall, potential help management NSCLC, but at present non-homogeneous literature data, lack optimal detection methods, together with relatively costs make its applicability routine diagnostics still challenging.

Language: Английский

Citations

10
Liquid biopsy: A noninvasive tool in breast cancer diagnosis and therapy response DOI
Riya Sharma,

Rimpy Charak,

Vijay Kumar

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 149 - 162

Published: Jan. 1, 2025

Language: Английский

Citations

0
Liquid Biopsy beim Mammakarzinom - schneller reagieren, besser behandeln DOI

Bianca Behrens,

Tanja Fehm, Jan‐Philipp Cieslik

et al.

InFo Hämatologie + Onkologie, Journal Year: 2025, Volume and Issue: 28(1-2), P. 15 - 19

Published: Feb. 1, 2025

Citations

0
Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment DOI Creative Commons
Hussein Sabit, Mohamed S. Attia,

Nouran Mohamed

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 6, 2025

Breast cancer management has traditionally relied on tissue biopsies and imaging, which offer limited insights into the disease. However, discovery of circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection revolutionized our approach to breast cancer. ctDNA, is fragmented found in bloodstream, provides a minimally invasive way understand tumor's genomic landscape, revealing heterogeneity critical mutations that may miss. MRD, indicates cells remain after treatment, can now be detected using ctDNA other advanced methods, improving ability predict recurrence. This allows for personalized adjuvant therapies based individual MRD levels, avoiding unnecessary treatments patients with low MRD. review discusses how represent paradigm shift towards personalized, genomically guided care, potential significantly improve patient outcomes

Language: Английский

Citations

0
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine DOI Open Access

Muhammad Zubair Afzal,

Linda T. Vahdat

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 719 - 719

Published: July 3, 2024

Breast cancer is the most common among women in world as well United States. Molecular and histological differentiation have helped clinicians optimize treatments with various therapeutics, including hormonal therapy, chemotherapy, immunotherapy, radiation therapy. Recently, immunotherapy has become standard of care locally advanced triple-negative breast an option across molecular subtypes for tumors a high tumor mutation burden. Despite advancements personalized medicine directing management localized cancers, emergence resistance to these therapies leading cause death patients. Therefore, there critical need identify validate predictive biomarkers direct treatment selection, potential responders, detect emerging therapies. Areas active scientific clinical research include novel incorporating microenvironment, immune profiling, characterization, histopathological predict response resistance.

Language: Английский

Citations

3
Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression DOI Creative Commons

Eva Valentina Klocker,

Samantha O. Hasenleithner, Rupert Bartsch

et al.

Molecular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: June 12, 2024

The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine are likely to transform standard clinical practice. non‐invasive nature this approach allows for molecular profiling entire entity, while also enabling real‐time monitoring effectiveness cancer therapies as well identification resistance mechanisms guide targeted therapy. Although field ctDNA studies offers a wide range applications, including early disease, review we mainly focus on role dynamic unresectable locally advanced metastatic BC (mBC). Here, provide practice guidance rapidly evolving mBC, outlining current landscape liquid biopsy applications how choose right assay. Additionally, underline importance exploring relevance novel alterations that potentially represent therapeutic targets along with mutations where therapy is already approved. Finally, present potential roadmap integrating analysis into

Language: Английский

Citations

2
Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy DOI
Tetsuhiro Yoshinami

Breast Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: April 23, 2024

Language: Английский

Citations

1
Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report DOI Open Access
Mariana Pilon Capella,

Parvaneh Fallah,

Mark Basik

et al.

Oncology Letters, Journal Year: 2024, Volume and Issue: 27(6)

Published: April 25, 2024

The detection of circulating tumor DNA (ctDNA) in the plasma cancer patients is emerging as a very sensitive and specific prognostic biomarker. Previous studies with ctDNA have focused on ability to predict micrometastatic eventual clinical metastatic relapse. There are few data role monitoring response local therapy. present study reports case patient early‑stage lobular breast cancer, detectable test which resolved radiotherapy breast. This suggests that enough detect minimal residual disease, localized breast, radiation therapy, thus may assist providing indications for treatment.

Language: Английский

Citations

1